\n| Subject<\/td>\n | \nFor restructuring of the group's investment structure,the\r\nBOD approved to acquire ASIA BEST LIFE CARE TECHNOLOGY \r\nCO.LTD.'s common shares from Excelsior Medical (HK) Co.,\r\nLtd.<\/pre>\n<\/td>\n<\/tr>\n\n| Date of events<\/td>\n | 2023\/08\/08<\/td>\n | To which item it meets<\/td>\n | paragraph 20<\/td>\n<\/tr>\n | \n| Statement<\/td>\n | \n1.Name and nature of the underlying assets (if preferred\r\n shares, the terms and conditions of issuance shall also\r\n be indicated, e.g., dividend yield,etc.):\r\n ASIA BEST LIFE CARE TECHNOLOGY CO.,LTD.49.38% common \r\n shares.\r\n2.Date of occurrence of the event:2023\/08\/08 ~ 2023\/08\/08\r\n3.Amount, unit price, and total monetary amount of the \r\n transaction: \r\n Amount:84,633,340 common shares.\r\n Unit price\uff1aUSD0.35522047 per share.\r\n Total monetary amount of transaction\uff1aUSD30,063,495 \r\n (NTD935,245 thousands)\r\n4.Trading counterparty and its relationship with the \r\n Company (if the trading counterparty is a natural \r\n person and furthermore is not a related party of the\r\n Company, the name of the trading counterparty is not\r\n required to be disclosed):The directly and indirectly\r\n holding 100% subsidiary.\r\n5.Where the trading counterparty is a related party, \r\n announcement shall also be made of the reason for \r\n choosing the related party as trading counterparty \r\n and the identity of the previous owner, its \r\n relationship with the Company and the trading \r\n counterparty, and the previous date and monetary \r\n amount of transfer:\r\n The reason for choosing the related party as trading\r\n counterpart: For restructuring of the group's \r\n investment structure.\r\n The identity of the previous owner, price of transfer,\r\n and date of acquisition:Not Applicable.\r\n6.Where an owner of the underlying assets within the \r\n past five years has been a related party of the \r\n Company, the announcement shall also include the\r\n date and price of acquisition and disposal by the \r\n related party, and its relationship with the Company \r\n at the time of the transaction:Not Applicable.\r\n7.Matters related to the current disposal of creditors'\r\n rights (including types of collaterals of the disposed\r\n creditor\u2019s rights; if creditor's rights over a related\r\n party, announcement shall be made of the name of the \r\n related party and the book amount of the creditor's \r\n rights, currently being disposed of, over such related\r\n party):Not Applicable.\r\n8.Profit or loss from the disposal (not applicable in \r\n cases of acquisition of securities) (those with \r\n deferral should provide a table explaining \r\n recognition): Not Applicable.\r\n9.Terms of delivery or payment (including payment period\r\n and monetary amount), restrictive covenants in the\r\n contract, and other important terms and conditions:\r\n Upon approval by Investment Commission,MOEA,the \r\n transfer of the target equity shall be carried out \r\n and completed.\r\n10.The manner of deciding on this transaction (such as \r\n invitation to tender,price comparison, or price \r\n negotiation), the reference basis for the decision on \r\n price,and the decision-making unit:It shall be handled\r\n in accordance with Article 3 and Article 5 of the \r\n \u201dProcedures for Acquisition and Disposal of Assets\u201d of\r\n Excelsior Medical Co., Ltd. Reference basis for the \r\n decision on price\uff1aValuation report issued by Diwan \r\n Financial Advisory Services Co.,Ltd\u3001Opinions on the \r\n reasonableness of transaction prices issued by A-Plus \r\n CPA Firm. \r\n Decision-making unit:\uff1aBoard of Directors.\r\n11.Net worth per share of the Company's underlying \r\n securities acquired or disposed of:Net worth per \r\n share:NTD 10.41\r\n12.Cumulative no.of shares held (including the current \r\n transaction), their monetary amount, shareholding \r\n percentage,and status of any restriction of rights \r\n (e.g., pledges), as of the present moment: \r\n Cumulative no. of shares held: 84,633,340 shares.\r\n Cumulative monetary amount:USD30,063,495 (NTD935,245 \r\n thousands)\r\n Shareholding percentage\uff1a49.38%\r\n restriction of rights: None.\r\n13.Current ratio of securities investment (including the\r\n current trade, as listed in article 3 of Regulations \r\n Governing the Acquisition and Disposal of Assets by \r\n Public Companies) to the total assets and equity \r\n attributable to owners of the parent as shown in the \r\n most recent financial statement and working capital as\r\n shown in the most recent financial statement as of the\r\n present:\r\n Ratio to total assets:70.77%\r\n Ratio to shareholders' equity of the parent company: \r\n 82.42%\r\n Amount of working capital:\uff1aNTD 1,274,323 thousands\r\n14.Broker and broker's fee:NO.\r\n15.Concrete purpose or use of the acquisition or \r\n disposal:For restructuring of the group's investment\r\n structure.\r\n16.Any dissenting opinions of directors to the present \r\n transaction:NO.\r\n17.Whether the counterparty of the current transaction is\r\n a related party:YES.\r\n18.Date of the board of directors resolution:2023\/08\/08\r\n19.Date of ratification by supervisors or approval by the\r\n Audit Committee:2023\/08\/08\r\n20.Whether the CPA issued an unreasonable opinion \r\n regarding the current transaction:NO.\r\n21.Name of the CPA firm:A-Plus CPA Firm.\r\n22.Name of the CPA:HUANG,SIN-JHONG\r\n23.Practice certificate number of the CPA:\r\n CPA Associations R.O.C.(Taiwan) No.1000088\r\n24.Whether the transaction involved in change of business\r\n model:NO.\r\n25.Details on change of business model:Not Applicable.\r\n26.Details on transactions with the counterparty for the \r\n past year and the expected coming year:Not Applicable.\r\n27.Source of funds:Not Applicable.\r\n28.Any other matters that need to be specified:None.<\/pre>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":" SEQ_NO \u00a03 Date of announcement 2023\/08\/08 Time of announcement 18:53:19 Subject For restructuring of the group’s investment structure,the BOD approved to acquire ASIA BEST LIFE CARE TECHNOLOGY CO.LTD.’s common shares from Excelsior Medical (HK) Co., Ltd. Date of events 2023\/08\/08 To which item it meets paragraph 20 Statement 1.Name and nature of the underlying …<\/p>\n For restructuring of the group’s investment structure,the BOD approved to acquire ASIA BEST LIFE CARE TECHNOLOGY CO. LTD.’s common shares from Excelsior Medical (HK) Co.,Ltd.<\/span> Read More »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[72,102],"tags":[],"class_list":["post-8461","post","type-post","status-publish","format-standard","hentry","category-investors","category-material-information"],"_links":{"self":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/8461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/comments?post=8461"}],"version-history":[{"count":13,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/8461\/revisions"}],"predecessor-version":[{"id":8490,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/8461\/revisions\/8490"}],"wp:attachment":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/media?parent=8461"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/categories?post=8461"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/tags?post=8461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} | |